Lung Carcinoma Antibodies

Santa Cruz Biotechnology features a diverse variety of Lung Carcinoma Antibodies for advanced research in cancer biology. Lung Carcinoma Antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Lung carcinoma is a leading cause of cancer-related mortality worldwide, and understanding its underlying mechanisms is crucial for developing effective therapies. Lung Carcinoma Antibodies target specific proteins that play significant roles in tumor growth, metastasis, and resistance to treatment, making them essential for elucidating the pathways involved in lung cancer progression. Studying molecular mechanisms can reveal potential biomarkers and therapeutic targets. Researchers can investigate cellular signaling pathways, protein interactions, and expression patterns using various detection methods. Secondary antibodies conjugated to horseradish peroxidase (HRP), phycoerythrin (PE), and fluorescein isothiocyanate (FITC) enable versatile detection options. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing scientific understanding of lung cancer and developing innovative therapeutic strategies.